Foghorn Therapeutics Inc.

FHTX

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Deerfield Management BVF Partners

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 3,649,211Value: $19.7M

**Signal Note: Deerfield Initiates $19.7M Position in Foghorn Therapeutics** Deerfield's entry into FHTX signals conviction in Foghorn's allosteric SHP2 inhibitor platform, particularly FHD-286 in KRAS-mutant cancers where the company expects Phase 2 data in 2024-2025. The $19.7M stake (3.6M shares) represents a meaningful bet by a sophisticated healthcare investor on a differentiated mechanism in an increasingly competitive KRAS space, though execution risk remains given earlier-stage pipeline maturity and recent market volatility in precision oncology.

BVF PartnersNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ANNX2 funds CMPS2 funds GPCR2 funds MIRM2 funds IRON2 funds STOK2 funds RVMD2 funds CGEM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: BVF Partners Initiates $28.6M Position in Foghorn Therapeutics BVF's entry into FHTX signals conviction in the company's proprietary chromatin biology platform, particularly FHD-286 (a PHD2 inhibitor in Phase 2 for polycythemia vera and other erythroid disorders) and FHD-609 (a BAF complex inhibitor). The 5.3M share position aligns with BVF's thesis on undercapitalized biotech with meaningful clinical inflection points; near-term catalysts include Phase 2 readouts and potential partnerships in chromatin-targeted oncology. This represents a baseline bet on platform validation rather than single-asset dependency.